Cargando…

Women's COPD

Chronic obstructive pulmonary disease (COPD) is no longer a respiratory disease that predominantly affects men, to the point where the prevalence among women has equaled that of men since 2008, partly due to their increasing exposure to tobacco and to biomass fuels. Indeed, COPD has become the leadi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zysman, Maéva, Raherison-Semjen, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761805/
https://www.ncbi.nlm.nih.gov/pubmed/35047517
http://dx.doi.org/10.3389/fmed.2021.600107
_version_ 1784633613595181056
author Zysman, Maéva
Raherison-Semjen, Chantal
author_facet Zysman, Maéva
Raherison-Semjen, Chantal
author_sort Zysman, Maéva
collection PubMed
description Chronic obstructive pulmonary disease (COPD) is no longer a respiratory disease that predominantly affects men, to the point where the prevalence among women has equaled that of men since 2008, partly due to their increasing exposure to tobacco and to biomass fuels. Indeed, COPD has become the leading cause of death in women in the USA. A higher susceptibility of female to smoking and pollutants could explain this phenomenon. Besides, the clinical presentation appears different among women with more frequent breathlessness, anxiety or depression, lung cancer (especially adenocarcinoma), undernutrition and osteoporosis. Quality of life is also more significantly impaired in women. The theories advanced to explain these differences involve the role of estrogens, smaller bronchi, impaired gas exchange in the lungs and smoking habits. Usual medications (bronchodilators, ICS) demonstrated similar trends for exacerbation prevention and lung function improvement in men and women. There is an urgent need to recognize the increasing burden of COPD in women and therefore to facilitate global improvements in disease management (smoking cessation, pulmonary rehabilitation…) in half of the population. Nevertheless, important limitations to the treatment of women with COPD include greater under-diagnosis than in men, fewer spirometry tests and medical consultations. In conclusion there is an urgent need to recognize the increasing burden of COPD in women and therefore to facilitate globally improvements in disease management in this specific population.
format Online
Article
Text
id pubmed-8761805
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87618052022-01-18 Women's COPD Zysman, Maéva Raherison-Semjen, Chantal Front Med (Lausanne) Medicine Chronic obstructive pulmonary disease (COPD) is no longer a respiratory disease that predominantly affects men, to the point where the prevalence among women has equaled that of men since 2008, partly due to their increasing exposure to tobacco and to biomass fuels. Indeed, COPD has become the leading cause of death in women in the USA. A higher susceptibility of female to smoking and pollutants could explain this phenomenon. Besides, the clinical presentation appears different among women with more frequent breathlessness, anxiety or depression, lung cancer (especially adenocarcinoma), undernutrition and osteoporosis. Quality of life is also more significantly impaired in women. The theories advanced to explain these differences involve the role of estrogens, smaller bronchi, impaired gas exchange in the lungs and smoking habits. Usual medications (bronchodilators, ICS) demonstrated similar trends for exacerbation prevention and lung function improvement in men and women. There is an urgent need to recognize the increasing burden of COPD in women and therefore to facilitate global improvements in disease management (smoking cessation, pulmonary rehabilitation…) in half of the population. Nevertheless, important limitations to the treatment of women with COPD include greater under-diagnosis than in men, fewer spirometry tests and medical consultations. In conclusion there is an urgent need to recognize the increasing burden of COPD in women and therefore to facilitate globally improvements in disease management in this specific population. Frontiers Media S.A. 2022-01-03 /pmc/articles/PMC8761805/ /pubmed/35047517 http://dx.doi.org/10.3389/fmed.2021.600107 Text en Copyright © 2022 Zysman and Raherison-Semjen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Zysman, Maéva
Raherison-Semjen, Chantal
Women's COPD
title Women's COPD
title_full Women's COPD
title_fullStr Women's COPD
title_full_unstemmed Women's COPD
title_short Women's COPD
title_sort women's copd
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761805/
https://www.ncbi.nlm.nih.gov/pubmed/35047517
http://dx.doi.org/10.3389/fmed.2021.600107
work_keys_str_mv AT zysmanmaeva womenscopd
AT raherisonsemjenchantal womenscopd